Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by I. Fusier
Pcn214 - Ibritumomab Tiuxetan Radiolabelled With Yttrium Chloride: 4 Years of Use in the 37 Public Hospitals of Paris and in France
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Related publications
Full-Dose 90Y Ibritumomab Tiuxetan Therapy Is Safe in Patients With Prior Myeloablative Chemotherapy
Clinical Cancer Research
Cancer Research
Oncology
Phase II Study of Yttrium-90-Ibritumomab Tiuxetan as Part of Reduced-Intensity Conditioning (With Melphalan, Fludarabine ± Thiotepa) for Allogeneic Transplantation in Relapsed or Refractory Aggressive B Cell Lymphoma: A GELTAMO Trial
Biology of Blood and Marrow Transplantation
Transplantation
Hematology
Radioimmunotherapy for B-Cell Lymphoma: Y90 Ibritumomab Tiuxetan and I131 Tositumomab
Oncogene
Cancer Research
Genetics
Molecular Biology
P53-Based Strategy for Protection of Bone Marrow From Y-90 Ibritumomab Tiuxetan
International Journal of Radiation Oncology Biology Physics
Oncology
Radiology
Cancer Research
Radiation
Nuclear Medicine
Imaging
MIRD Dose Estimate Report No. 20: Radiation Absorbed-Dose Estimates for 111In- And 90y-Ibritumomab Tiuxetan
Journal of Nuclear Medicine
Medicine
Nuclear Medicine
Radiology
Imaging
A New Pharmacokinetic Model for 90y-Ibritumomab Tiuxetan Based on 3-Dimensional Dosimetry
Scientific Reports
Multidisciplinary
Positron Emission Tomography/Computed Tomography Before Treatment as a Predictor of 90y-Ibritumomab Tiuxetan Response
Kitakanto Medical Journal
Medicine
90 Y-Ibritumomab Tiuxetan in Patients With Extra-Nodal Marginal Zone B-Cell Lymphoma of Mucosa Associated Lymphoid Tissue (Malt Lymphoma) - The Zeno Study
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Public and Semi-Public Corporations in France
Law and Contemporary Problems
Law
